Absolute versus change in pulmonary vascular resistance in relation to European Society of Cardiology/European Respiratory Society risk change in pulmonary arterial hypertension

Donker, SCM ORCID: 0000-0002-8019-8699, Wild, CJB, Augustine, DX, Suntharalingam, J, Ross, RVMK, van Dijk, APJ, Maxwell, JD, Oxborough, D ORCID: 0000-0002-1334-3286 and Thijssen, DHJ ORCID: 0000-0002-7707-5567 (2026) Absolute versus change in pulmonary vascular resistance in relation to European Society of Cardiology/European Respiratory Society risk change in pulmonary arterial hypertension. JHLT Open, 13. p. 100599. ISSN 2950-1334

Preview

Text Absolute versus change in pulmonary vascular resistance in relation to European Society of Cardiology European Respiratory Society risk change in pulmonary arterial hypertension.pdf - Published Version Available under License Creative Commons Attribution. Download (2MB) | Preview

Abstract

Introduction: In pulmonary arterial hypertension (PAH), it remains unclear whether absolute haemodynamic values or treatment-induced changes are more relevant to subsequent changes in clinical status. As risk classifications are increasingly used to guide clinical management, we evaluated whether pulmonary vascular resistance (PVR) at baseline, after 4 months of therapy, or treatment-induced change better explains risk change. Methods: Among 104 screened PAH patients, 69 were included retrospectively. The primary outcome was change in clinical status, defined as a shift in ESC/ERS 4-strata risk classification from baseline to 15 months. Haemodynamics were evaluated via right heart catheterization before and after 4 months of pharmacotherapy. Linear regression examined associations of baseline PVR, 4-month PVR, and ΔPVR with risk change. ROC analyses explored the ability of PVR (baseline, 4-month, and Δ), ΔRVEDP, and ΔCI to discriminate between risk stabilization and worsening. Results: Risk classification and PVR decreased significantly following treatment (p<0.001). ΔPVR had the highest partial explained variance for risk change (R²=0.118, p=0.003), followed by baseline PVR (R²=0.098, p=0.013). Four-month PVR did not significantly predict risk classification change. In ROC analyses, only ΔPVR significantly discriminated risk stabilization (AUC=0.75, p<0.001). Bootstrapping and permutation confirmed the robustness of these findings. Conclusions: The change in PVR after 4 months of treatment outperformed baseline and 4-month PVR, but also other dynamic measures (ΔRVEDP and ΔCI), in explaining changes in 4-strata risk classification and identifying risk stabilization. These findings suggest that ΔPVR provides complementary insight when interpreting serial haemodynamic evaluations in the context of early treatment response in PAH.

Item Type:	Article
Uncontrolled Keywords:	Pulmonary arterial hypertension; haemodynamic changes; pulmonary vascular resistance; right heart catheterization; risk stratification; treatment response; 32 Biomedical and Clinical Sciences; 3202 Clinical Sciences; Rare Diseases; Lung; Cardiovascular; Orphan Drug; Cardiovascular
Subjects:	R Medicine > R Medicine (General) R Medicine > RC Internal medicine > RC1200 Sports Medicine
Divisions:	Sport and Exercise Sciences
Publisher:	Elsevier
Date of acceptance:	16 May 2026
Date of first compliant Open Access:	21 August 2026
Date Deposited:	21 Aug 2026 14:03
Last Modified:	21 Aug 2026 14:03
DOI or ID number:	10.1016/j.jhlto.2026.100599
URI:	https://researchonline.ljmu.ac.uk/id/eprint/29181

View Item